PHARMACOLOGICAL INHIBITION OF ADENYLYL CYCLASE TYPE 5: A NOVEL THERAPEUTIC MODALITY TO REDUCE INFARCT SIZE EVEN WHEN DELIVERED AFTER CORONARY ARTERY REPERFUSION
| Autor: | Dorothy E. Vatner, Jie Zhang, SeongHun Yoon, Stephen F. Vatner, Christopher Meenan, Thomas Richardson, Daniel Levy |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Drug
medicine.medical_specialty Modality (human–computer interaction) business.industry media_common.quotation_subject medicine.disease Infarct size Adenylyl cyclase chemistry.chemical_compound medicine.anatomical_structure chemistry Internal medicine Cardiology medicine In patient Myocardial infarction Cardiology and Cardiovascular Medicine business media_common Artery |
| Zdroj: | Journal of the American College of Cardiology. 71:A9 |
| ISSN: | 0735-1097 |
| DOI: | 10.1016/s0735-1097(18)30550-3 |
| Popis: | One of the key reasons why reducing myocardial infarct (MI) size in patients has largely has been unsuccessful is that the drug must be delivered after coronary artery (CA) reperfusion (CAR) to be successful, since in the clinical setting CAR must precede other therapeutic interventions. It is also |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|